Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MacuCLEAR Inc.

This article was originally published in Start Up

Executive Summary

MacuCLEAR's lead molecule for AMD, based on a marketed anti-hypertensive, stimulates choroidal blood flow so that cellular wastes in the eye can be cleared and never cause the breakdown of critical tissues that diminish vision. The company has received IND clearance to shepherd its treatment down the 505(b)(2) approval pathway with fast track status.

You may also be interested in...



Acucela Inc.

Acucela is developing oral compounds that can possibly slow or stop vision loss caused by dry age-related macular degeneration. Its lead candidate is a small-molecule inhibitor of an enzyme called RPE65, known to be involved in the build-up of A2E, a toxic vitamin A by-product that is implicated in AMD.

Sirion Therapeutics Inc.

Fenretinide, Sirion Therapeutics' lead candidate, targets the pathway by which Vitamin A gets into the eye and becomes part of A2E, the protein complex that scientists consider a bad actor in AMD. Intermediate analysis of fenretinide Phase II data showed that patients taking the compound had slower growth of lesions than those given placebo, and that trend increased over time.

Iconic Therapeutics Inc.

Iconic Therapeutics is targeting tissue factor, a protein that decorates pathological vessels but is not found on normal tissue. The start-up has created a bi-functional protein capable of homing in on TF-laden cells and triggering their destruction. Studies in animal models of AMD show that injection of the therapy results in the regression of up to 50% of unwanted blood vessels.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel